Document Detail


Update on pharmacologic management of OCD: agents and augmentation.
MedLine Citation:
PMID:  9393391     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A preponderance of patients with obsessive-compulsive disorder (OCD) experience little or no improvement in their symptoms when treated with serotonin reuptake inhibitors (SRIs). It is hypothesized that SRI-refractory patients may have altered serotonin neurotransmission different from patients responsive to SRIs, or that they may have abnormalities in their dopamine function. When drugs affecting serotonin function (e.g., tryptophan, fenfluramine, lithium, buspirone) are added to SRI therapy in SRI-refractory patients, results are mixed and not consistently encouraging. However, when drugs affecting dopamine function (e.g., pimozide, haloperidol, risperidone) are added to SRI therapy in SRI-refractory OCD patients, individuals with either a personal history or family history of tics experience a reduction in their symptoms.
Authors:
C J McDougle
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  The Journal of clinical psychiatry     Volume:  58 Suppl 12     ISSN:  0160-6689     ISO Abbreviation:  J Clin Psychiatry     Publication Date:  1997  
Date Detail:
Created Date:  1997-12-15     Completed Date:  1997-12-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7801243     Medline TA:  J Clin Psychiatry     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  11-7     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Yale University School of Medicine, New Haven, Conn., USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Clozapine / therapeutic use
Dopamine Agents / therapeutic use*
Drug Therapy, Combination
Female
Fenfluramine / therapeutic use
Haloperidol / therapeutic use
Humans
Lithium / therapeutic use
Middle Aged
Obsessive-Compulsive Disorder / drug therapy*,  psychology
Serotonin Agents / therapeutic use*
Serotonin Uptake Inhibitors / therapeutic use*
Treatment Outcome
Tryptophan / therapeutic use
Grant Support
ID/Acronym/Agency:
MH25642/MH/NIMH NIH HHS; MH30929/MH/NIMH NIH HHS; MH45802/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Dopamine Agents; 0/Serotonin Agents; 0/Serotonin Uptake Inhibitors; 458-24-2/Fenfluramine; 52-86-8/Haloperidol; 5786-21-0/Clozapine; 73-22-3/Tryptophan; 7439-93-2/Lithium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Epidemiology of obsessive-compulsive disorder: a world view.
Next Document:  Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.